N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phen

CAS: 1315330-11-0

Ref. 3D-FE103676

Produktinformation

• Name: N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phen

Beschreibung

N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phen] (NEOF) is a potent inhibitor of the b-raf kinase and is used in cancer treatment. NEOF has been shown to inhibit epidermal growth factor receptor (EGFR)-mediated cell signaling, which may be due to its ability to induce autophagy. NEOF has also been shown to have cytotoxic effects on melanoma cells with BRAF mutations, which can lead to the death of these cells. The clinical relevance of NEOF in the treatment of skin cancer remains unclear.

NEOF has a linear pharmacokinetic profile in humans and is metabolized by cytochrome P450 enzymes before being excreted as a glucuronide conjugate. This drug binds tightly to plasma proteins (>99%) and has little potential for drug interactions due to its low protein binding affinity.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 552.59 g/mol
• Formel: C₂₉H₃₁F₃N₆O₂
• Reinheit: Min. 95%